All Industries

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Benzinga

By Anthony Termini, Benzinga In August 2020, popular actor Chadwick Boseman succumbed to colorectal cancer at the age of 43 after a four-year battle with colon cancer. The untimely death of the Black Panther star saw many fans overcome with grief but also brought attention to the danger posed by such cancers. Colorectal cancer is the second leading cause of cancer death in the United States, with more than 100,000 cases diagnosed so far in 2024. Mainz Biomed (NASDAQ: MYNZ), a German company whose U.S. offices are in Berkeley, California, believes the threat can be mitigated by technology and is working on a predictive test that may be more effective than solutions currently on the market. Benzinga recently sat down with the company’s CFO, Bill Caragol, to discuss the challenge and all the work the company is doing to help address it. The Available Options For Detecting Colorectal Cancer The standard of care for detecting colorectal cancer has since 1969 been the colonoscopy. The procedure is invasive and not very pleasant. In 2014, the fecal immunochemical test (FIT) received FDA approval. The test analyzes a person’s DNA to detect advanced adenomas, the pre-cancerous polyps that “may be the most valid…marker for present and future colorectal cancer risk,” according to research published by the National Library of Medicine. Blood-based tests are also available to detect colorectal cancer risk. However, some in the medical community are cautious about their use. According to David Lieberman, MD, chair of the American Gastroenterological Association’s Colorectal Cancer Workshop, “blood tests are neither as effective or cost-effective" as established colorectal cancer screening tests – something that Mainz’s Caragol testifies to, as well, stating that doctors continue to prescribe stool-based tests over blood tests because of the clinical differentiation since stool-based tests are better at detecting early-stage cancer, despite the “yucky factor.” He added,”Remember, [with] colorectal cancer – you detect late-stage, there’s a roughly 10% survival. When you catch it in early-stage, there’s 90% survival.” Mainz’s Breakthrough Device Leads To Next-Generation Screening Test Mainz has developed a molecular diagnostic solution to detect colon cancer risk. In July, Mainz submitted an application to the U.S. Food and Drug Administration (FDA) requesting Breakthrough Device Designation for a non-invasive colorectal cancer product that includes a portfolio of mRNA biomarkers. Studies conducted by Mainz revealed that its mRNA-powered test showed a sensitivity for detecting precancerous polyps that is double that of products currently on the market. In those studies, competitors’ tests “demonstrated efficacy of detecting advanced adenomas in the 40% range,” says Bill Caragol. Caragol added that readouts from the three clinical studies Mainz conducted between 2023 and 2024, “demonstrated consistent accuracy above 80%, a quantum leap...over the other stool-based tests.” Mainz says its flagship product, ColoAlert®, misses far fewer cases than its competitors’ tests. Mainz puts the number at up to 60% fewer cases. Its next-generation FIT test is an enhancement of ColoAlert and was submitted to the FDA in July for Breakthrough Device designation. The next-generation FIT test is complemented by a proprietary algorithm that uses artificial intelligence and machine learning to identify mRNA biomarkers in order to better detect the early warning signals of potential colorectal cancer. Mainz said the test is “a new gold standard for noninvasive detection of advanced adenomas.” The company is scheduled to conduct an FDA pre-market approval study in 2025 for its next-generation test. A focus of the study is to distribute the next-generation test kit through the currently existing network of FDA-approved national reference testing laboratories in the United States. This differs from other products currently on the market in that the companies that make those test kits also control the testing process. As Caragol describes it, “every test [is] manufactured by them, sent out by them, returned to them [for analysis], test results delivered.” As a result, says Caragol, Mainz will have “the only product that will fit into the largest distribution.” Milestones Mainz Is Focused On For The Year Ahead Mainz has a clear strategy for approaching the market. Caragol said that they realize that as a small company targeting a large market, they will have to strategically align themselves with larger companies. The company is looking to partner with a PCR provider as well as one of the national reference labs. PCR labs specialize in blood, urine and other molecular testing to detect pathogens, commonly used for diagnosing infections like COVID-19. National reference labs offer a wide range of high-accuracy diagnostic services, including PCR, serving as centralized hubs for specialized testing across various locations. Having these partnerships in place is necessary for Mainz to conduct its FDA pre-market approval study. Importantly, they will also be important allies if the company receives approval to sell the kits. They will be integral components of Mainz’s commercial go-to-market strategy. At that point, Mainz’s commercial roadmap will focus on creating partnerships and awareness within physician networks and health care professionals about the differentiating benefits of the ColoAlert mRNA powered test. Investment Drivers For Companies Like Mainz Biomed If the company can meet each of its milestones, then it could set a course for future growth. The U.S. market for colorectal screening “is over $30 billion a year,” according to Caragol. He notes that the market is double that worldwide. There are a number of companies competing domestically for colorectal screening, the most notable of which is Exact Sciences Corp. (NASDAQ: EXAS). Caragol says Exact has about a 10% share of U.S. sales. As such, there may be an opportunity for Mainz if its next-generation test receives FDA approval in the next few years. The company says that a successful launch could open the door to other products, including test kits for pancreatic and other gastrointestinal cancers – significantly expanding its addressable market. For more information about Mainz Biomed listen to the conversation Bill Caragol had with Benzinga’s Zunaid Suleman. Featured photo by Furiosa-L from Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:35 AM Eastern Daylight Time

Image

AJNA BioSciences’ Strategy For Market Leadership In Botanical Drug Development With Magic Mushrooms And Cannabis

Benzinga

By Anthony Termini, Benzinga Individual investors can own equity in AJNA BioSciences on the same terms as venture capitalists and professional angels. Click here for details. Consumers are increasingly demanding natural health solutions, with recent surveys demonstrating that a majority of consumers believe products with natural ingredients are healthier and that botanical supplements are effective. Many people believe that “food should be medicine.” Littleton, Colorado-based AJNA Biosciences says it is aiming to build a bridge “between what people want, and physician advocacy they can trust.” AJNA's Pharmaceuticals Come From Nature Backed By Science AJNA is focused on developing a new class of drugs derived from botanicals. The company is exploring plant and fungi species with therapeutic compounds that address specific conditions. “The future of medicine is actually millions of years old,” says Joel Stanley, CEO of AJNA. This ethos is guiding AJNA’s development of two drug candidates focused on treating conditions that it estimates today affect more than 80 million people. The company’s research team, led by scientists from Harvard, Johns Hopkins and New York University, are working on botanical drugs to treat or support people with Autism Spectrum Disorder and Generalized Anxiety Disorder. Today, there is no FDA-approved natural remedy for either of these conditions, reports AJNA. They can both be treated with synthetic compounds engineered by big pharmaceutical companies, but those drugs can come with a number of unpleasant side effects. AJNA distinguishes itself by participating in the evolving field of botanical drug development and is pioneering a new regulatory pathway to produce drugs from plant medicine that are ultimately approved by the U.S. Food and Drug Administration (FDA). AJNA has advanced the development of two prescription drug candidates by standardizing botanical raw materials to meet strict FDA guidelines. The first drug candidate, CBD for Autism Spectrum Disorder (ASD), is preparing to enter phase 2 clinical trials with an upcoming Investigational New Drug (IND) filing, while the second candidate, Psilocybin for Generalized Anxiety Disorder (GAD), is approaching phase 1. The two drugs in development are a full-spectrum cannabis-derived drug and a psilocybin-based antidepressant. AJNA says it will look to expand indications for these products beyond autism and anxiety to also include post-traumatic stress disorder, various sleep disorders, attention-deficit/hyperactivity disorder and chronic pain. A Holistic Approach Based On Ethics And Sustainability AJNA believes it is tapping into rising consumer demand for holistic treatment options that include natural remedies. The company says that demand has never been higher. As part of the company’s ethos, it is committed to sustainable methods in its research and development processes. It is also committed to reducing its ecological footprint. AJNA follows Stanley's previous venture, a company he founded with his brothers called Charlotte’s Web Holdings (OTC: CWBHF). It started out as a mission not a company, giving away an extract to those who could benefit, then gained public recognition after the CBD oil was being used to treat seizures in 5-year-old Charlotte Figi. The company prioritizes minimizing the use of unnecessary and potentially harmful chemicals. AJNA's psilocybin drug is processed using only the water from the fungi itself, without any added agents or artificial chemicals. If this drug gains FDA approval, it could be one of the few organic options available on the market. Additionally, the company's commitment to environmental sustainability results in a largely organic waste stream, which is repurposed as compost and used as a soil amendment throughout the Denver area. AJNA Could Be Poised To Benefit From Significant Shifts In Perception The demand for psychedelic-assisted therapy is increasing at a time when the FDA is defining new drug development pathways for botanical drugs to get approved. This is helping AJNA build a bridge between what people want and the physician advocacy necessary to gain wider public trust. The company’s Chief Medical Advisor, Orrin Devinsky, is one of the first clinicians to research cannabinoids. His work as principal investigator led to the development of Epidiolex, the only FDA-approved cannabis-derived drug currently on the market. “It is important for us to provide a [botanical] option that has clinical science behind it, so doctors can get behind it, so insurance can cover it for people in the future,” said Stanley about AJNA’s research and development and pending clinical trials. AJNA also gains an advantage from unique intellectual property regulations that protect botanical drugs. Plant variety patents provide 20 years of protection, significantly longer than the five to seven years typically granted to synthetic drug compounds. Big Pharma May Look To Botanicals For Future Growth AJNA believes that major pharmaceutical and biotechnology companies will increasingly recognize the therapeutic and commercial potential of botanical drugs. Cannabinoids and psychedelics could be part of future opportunities for large players to acquire or merge with smaller botanical drug companies. This is part of an established playbook in the biotech industry. A small company’s successful drug development platform creates potential liquidity for investors. This may include the acquisition of a single drug candidate or the entire company. In many cases, these acquisitions take place before the target company begins to generate revenue. In AJNA’s case, the company is working with Wefunder to help it raise capital. Wefunder is a public benefit corporation with a goal to “fix capitalism” in addition to helping companies create shareholder value. More information is available on the Wefunder website. Featured photo courtesy of AJNA BioSciences. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

September 03, 2024 08:30 AM Eastern Daylight Time

Image

NAVEX Announces 2024 Excellence Awards Finalists

NAVEX Global

NAVEX, a leading provider of integrated risk and compliance management software, announces today the 2024 NAVEX Excellence Awards finalists. Now in its fourth year, the awards celebrate organizations that demonstrate exceptional commitment to corporate governance, risk mitigation, and ethical practices. Each year, the NAVEX Excellence Awards highlight how robust governance, risk and compliance (GRC) programs can strengthen corporate culture and meaningfully impact business outcomes that matter. The 2024 finalists exemplify how effective GRC initiatives can proactively manage and mitigate risks when woven into the organizational fabric. "Congratulations to this year’s nominees and finalists for their outstanding achievements," said NAVEX Chief Customer Officer, Steve Chapman. "We are proud to partner with customers who are dedicated to advancing their GRC efforts. These awards shine a spotlight on some of the most innovative and effective programs in the industry, and we applaud the compliance teams at these companies for their ongoing efforts to build highly ethical, risk-aware organizations." The winners will be honored in several categories, including Ethics & Compliance, Risk Management, and Risk and Compliance Program of the Year. Selected from a highly competitive pool of nominations, this year’s finalists include: As in previous years, the judging panel brings together a mix of NAVEX leaders and seasoned GRC professionals. This year’s esteemed panel features: Barbara Boehler, Senior Director, Program on Corporate Compliance and Ethics, Fordham Law Bill Cameron, Founder and Principal, Cameron Advisory Services Carol Williams, CEO and Enterprise Risk Management Consultant, Strategic Decision Solutions Carrie Penman, Chief Risk and Compliance Officer, NAVEX Kyle Brasseur, Former Editor in Chief, Compliance Week Kyle Martin, Vice President of GRC Solutions, NAVEX Matt Kelly, Editor and CEO, Radical Compliance LLC Stephen Chapman, Chief Customer Officer, NAVEX Vera Cherepanova, Ethics Advocate, Consultant, Author, Studio Etica Award recipients will be announced after to the 2024 NAVEX Next Virtual Conference on October 1. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

September 03, 2024 08:06 AM Eastern Daylight Time

News Release

Strong Management and Partners Make Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF) a Compelling Opportunity

Railtown AI

Artificial intelligence has rapidly evolved from a futuristic concept to a central component of modern business strategy. With the AI market projected to surge from $196.63 billion in 2023 to transformative levels by 2030, businesses across all sectors are leveraging AI to boost efficiency, cut costs, and secure a competitive advantage. From automating complex tasks to enhancing customer interactions, AI is revolutionizing industries. As the AI sector expands, investors are increasingly turning their attention to companies driving this innovation. One standout example is Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF), a company poised to make significant waves in the industry. Railtown AI Technologies Inc. is emerging as a standout player in the artificial intelligence landscape, driven by its robust management team and strategic partnerships. The company's focus on AI solutions, particularly through its innovative Conductor AI platform, underscores its potential to transform various sectors. Core Technology and Offerings Railtown's cloud-based Application General Intelligence Platform stands out for its flexibility, supporting both cloud and on-premise deployments. It uses machine learning to adapt from connected applications, which enhances decision-making and reduces operational costs. The platform’s real-time processing capabilities are crucial for efficient software development. Key Features Root Cause Analyzer: Identifies and prioritizes errors, saving developers over eight hours a week and reducing maintenance costs. Conductor AI Assistant: Provides instant, natural language responses to development queries and continuously improves based on user feedback. Velocity Dashboard: Tracks performance metrics, aiding management in planning and resource allocation. Release Notes Automator: Generates clear release notes in under two minutes, ensuring consistency and saving time. Ticket Generator: Uses AI to streamline ticket creation, minimizing manual input and allowing more focus on coding. API No-Code Virtual Developer: Enables users to create new functionalities without coding skills, democratizing development and boosting productivity. Strategic Partnerships Railtown AI Technologies Inc.’s partnerships play a crucial role in amplifying its technological capabilities and market reach. In July 2024, RALIF secured a strategic alliance with Mila, the Quebec Artificial Intelligence Institute, under the leadership of Professor Yoshua Bengio. This partnership provides Railtown with access to Mila’s cutting-edge research and a network of AI experts. It allows Railtown to integrate the latest advancements in deep learning into its Conductor AI platform, further enhancing its technological prowess. Mila’s involvement also aids in talent acquisition and training, ensuring that Railtown remains at the forefront of AI innovation. Similarly, Railtown AI's collaboration with the Alberta Machine Intelligence Institute (Amii), announced in July 2024, is instrumental in advancing its capabilities. Amii’s expertise in reinforcement learning and natural language processing complements Railtown’s technology, contributing to the refinement of its AI solutions. This partnership brings additional expertise and resources to Railtown, accelerating the development of sophisticated AI applications. Furthermore, Railtown retains ownership of all intellectual property developed through this collaboration, which strengthens its competitive position in the market. The company's earlier partnership with Quisitive Technology Solutions Inc. highlights its commitment to practical applications of AI. This integration incorporates Railtown’s AI technology into Quisitive’s Velocity Insights toolset, enhancing software engineering productivity and project management. This partnership showcases Railtown’s ability to apply its technology effectively in real-world scenarios, expanding its influence within enterprise environments. Leadership Driving Innovation Railtown AI’s leadership team is a key asset, guiding the company through its growth and innovation journey. Cory Brandolini, Founder and CEO, brings over 30 years of experience in technology and software ventures. His background includes raising significant capital for technology companies and leading successful exits, such as the acquisition of Teleo Inc. by Microsoft. Brandolini’s strategic vision and industry connections are vital for steering Railtown AI towards its ambitious goals. Co-Founder and CTO Marwan Haddad contributes over 25 years of experience in software development, having led engineering teams at major tech platforms like RESAAS and Fortune 500 companies. Haddad’s technical expertise ensures that Railtown’s AI solutions are developed and executed to the highest standards. Dr. Elliot Holtham, Co-Founder and AI Data Scientist, brings extensive experience in machine learning and data science. His previous role at Xtract AI, acquired by Patriot One Technologies, and his academic achievements bolster Railtown’s R&D efforts and drive innovation within its technology offerings. Kevin O’Neil, Advisory Chair, offers a wealth of experience in technology investing and advisory roles. His previous role as CEO of Xtract AI and his expertise in strategic guidance and investment reinforce Railtown’s market strategy and growth trajectory. Conclusion Railtown AI Technologies Inc. represents an intriguing investment opportunity, distinguished by its innovative Conductor AI platform, strategic partnerships, and a seasoned leadership team. The collaborations with Mila and Amii enhance Railtown’s technological capabilities and research potential, while the partnership with Quisitive illustrates the practical application of its AI solutions. With a management team renowned for its expertise and a clear focus on delivering advanced AI technologies, Railtown AI Technologies Inc. (CSE: RAIL) (OTCQB: RLAIF) could be a stock to watch for continued success in the evolving artificial intelligence sector. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by Awareness Consulting to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

September 03, 2024 06:00 AM Eastern Daylight Time

Aligning Investment Strategies through the Health Care Select Sector SPDR Fund (XLV)

Select Sector SPDR

In the evolving landscape of healthcare, the Health Care Select Sector SPDR Fund (XLV) stands as an investment vehicle for those looking to diversify their portfolio within the U.S. healthcare sector. By tracking healthcare stocks within the S&P 500 Index, XLV offers broad exposure to foundational companies that are central to healthcare in America. Featuring a blend of leading entities across various sub-sectors, XLV's holdings provide investors with exposure to many of the healthcare sector’s diverse industries. Highlighting XLV's Key Holdings* The fund's composition showcases a selection of companies pivotal to healthcare’s wide-ranging facets: Eli Lilly (LLY) - 11.66% UnitedHealth (UNH) - 9.63% Johnson & Johnson (JNJ) - 6.90% AbbVie (ABBV) - 5.94% Merck (MRK) - 5.20% Thermo Fisher Scientific (TMO) - 4.25% Abbott Labs (ABT) - 3.35% Danaher (DHR) - 3.32% Amgen (AMGN) - 3.24% Pfizer (PFE) - 3.14% These holdings span pharmaceuticals, health insurance, medical devices, and diagnostics, illustrating the fund's encompassing approach to the healthcare sector. Sector Dynamics Influencing Healthcare Engagement The healthcare sector is characterized by factors such as demographic trends, technological advancements, and shifts in healthcare delivery models. These elements contribute to the sector's role within the broader economy and its relevance to consumer needs. Healthcare spending's share of Gross Domestic Product (GDP) has maintained a significant position, reflecting the sector's integral role in the economic landscape. This dynamic underscores the steady relevance of healthcare in consumer and governmental expenditure. The Strategic Appeal of the XLV Fund Investing in the Health Care Select Sector SPDR Fund (XLV) allows individuals to engage with the healthcare sector through a vehicle that offers balanced and diversified exposure. The fund's structure is designed to mitigate the risks associated with investing in individual companies by providing a portfolio that reflects the sector's breadth. For investors seeking a methodical approach to incorporating healthcare into their investment portfolios, XLV presents a tactful option. The fund's focus on core healthcare companies, coupled with its diversified strategy, affords a stable pathway to participation in the sector's activities. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 7/31/24 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007756 EXP 10/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

September 02, 2024 05:00 AM Eastern Daylight Time

News Release

Commerce Finds Dumping; Imposes Duties on Paper Plates from China, Vietnam, and Thailand

American Paper Plate Coalition

The American Paper Plate Coalition (“APPC”), representing the majority of American paper plate production, announced today that the U.S. Department of Commerce (Commerce) has made preliminary affirmative findings in the antidumping (AD) duty portion of investigations involving paper plate imports from China, Vietnam and Thailand, and imposed preliminary AD duties up to 1039.05 percent. The duties will take effect on or about September 6, 2024. These duties will be imposed on top of anti-subsidy duties of up to 313.14 percent on imports from China and up to 237.65 percent on imports from Vietnam, levied in preliminary decisions released in June 2024. Preliminary duties now total up to 1352.19 percent on imports from China, up to 397.44 percent on imports from Vietnam, and up to 73.17 percent on imports from Thailand. “Improper subsidies and other unfair trade practices have hurt our industry, our company, and our workers over the years,” said William P. Biggins, Jr., President and Co-Owner of APPC member Aspen Products, Inc. “The duties announced today are a welcome step in the right direction to get the market back on track. We are grateful to Commerce for its commitment to seeing our trade laws enforced and for giving all players a chance to fairly compete.” Commerce’s preliminary determinations come in response to petitions filed in January by the APPC, requesting AD and CVD investigations into unfairly priced and subsidized imports of paper plates from China, Thailand, and Vietnam. Commerce is expected to announce its final AD determinations in these investigations in early November 2024. The countervailing duty investigations concerning imports from China and Vietnam are ongoing and may lead to higher final CVD rates. “We welcome the competition of a free and fair market – but that’s not what we’ve been experiencing,” said Robert Epstein, President and CEO of APPC member AJM Packaging Corporation. “We look forward to getting back on a level playing field where all products compete on their own merits. Today’s decision is another step in getting us there.” If Commerce makes affirmative final determinations and the U.S. International Trade Commission makes an affirmative final injury determination, Commerce will issue formal AD and CVD orders on imports from all three countries. For more on the petitions, see the APPC’s press release. For more on the ITC’s investigation, see the Commission’s press release. For more on the DOC’s investigation, see the agency’s press release. About the American Paper Plate Coalition The American Paper Plate Coalition, representing the leading U.S. producers of paper plates, is comprised of AJM Packaging Corporation of Bloomfield Hills, MI; Aspen Products, Inc. of Kansas City, MO; Dart Container Corporation of Mason, MI; Hoffmaster Group, Inc. of Oshkosh, WI; Huhtamaki, Inc., of De Soto, KS; and Unique Industries, Inc. of Philadelphia, PA. For more information, visit https://www.ajmpack.com/, https://www.aspenpro.com/, https://www.dartcontainer.com/, https://www.hoffmaster.com/, https://www.huhtamaki.com/en-us/north-america/, and https://www.favors.com/ The American Paper Plate Coalition is represented by Adam H. Gordon of The Bristol Group PLLC, a Washington, DC international trade law firm committed to defending American industry, agriculture, and manufacturing jobs. Contact Details Elizabeth Posthumus +1 202-445-9858 elizabeth@eahstrategiesllc.com

August 30, 2024 01:14 PM Eastern Daylight Time

Justin Sun Presents Keynote Speech at WebX 2024, TRON DAO Featured as Title Sponsor

TRON DAO

Geneva, Switzerland, August 30, 2024 - WebX 2024, a global Web3 conference organized by CoinPost, welcomed TRON DAO as a Title Sponsor and welcomed its visionary founder, Justin Sun, as a keynote speaker. Additionally, TRON DAO played a key role as a Platinum Sponsor at OKJ Night and a sponsor at the WebX Official Afterparty. WebX 2024 is a premier global Web3 conference organized and managed by CoinPost, Japan's largest Web3 media. As one of Asia's largest gathering of professionals in the crypto, blockchain, and Web3 spaces, WebX 2024 brought together companies, experts, entrepreneurs, investors, government officials, and media from Japan and abroad, creating a unique space for direct interaction and collaboration. TRON DAO played an integral role at WebX 2024, engaging in multiple sessions and making substantial contributions to the dynamic discussions and networking opportunities that the event provided. Justin Sun’s Keynote In his keynote, Sun emphasized the critical role of building dynamic and diverse ecosystems that genuinely empower communities. He articulated how the TRON blockchain ecosystem is an environment where everyone can discover their place and contribute meaningfully. Sun's commitment to building solutions that empower individuals and bring communities together has been one of the contributing forces behind TRON's rapid growth, highlighting how a people-first philosophy can lead to significant advancements in the blockchain space. WebX Official Afterparty The official afterparty, sponsored by TRON DAO, took place at Zouk Tokyo, where speakers, VIP guests, and participants gathered to celebrate the final day of WebX. The event provided a vibrant setting for attendees to unwind, network, and reflect on the conference's success while enjoying music, drinks, and the dynamic atmosphere that encapsulated the spirit of innovation and collaboration fostered throughout the event. OKJ Night As an official side event of WebX, OKJ Night stood out as a memorable celebration, marking the significant rebranding of OKCoinJapan to OKJ. Supported by TRON DAO as a Platinum Sponsor, the event gathered industry leaders, setting the stage for future growth and collaboration in the blockchain space. WebX 2024 was a remarkable convergence of innovation and collaboration, with TRON DAO at the forefront as a Title Sponsor. The conference underscored the power of building diverse and dynamic ecosystems, a vision articulated by Justin Sun in his keynote speech. His focus on community empowerment and the inclusive nature of the TRON ecosystem resonated deeply, highlighting how blockchain can drive meaningful change. With TRON DAO’s involvement as a Platinum Sponsor at the OKJ Night and sponsor at the WebX Official Afterparty, the event truly embodied the spirit of unity and progress. As the blockchain industry continues to evolve, TRON DAO remains committed to fostering environments where innovation can thrive and communities can flourish. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON network has continued to deliver impressive achievements since MainNet launch in May 2018. July 2018 also marked the ecosystem integration of BitTorrent, a pioneer in decentralized Web3 services boasting over 100 million monthly active users. The TRON network has gained incredible traction in recent years. As of August 2024, it has over 252 million total user accounts on the blockchain, more than 8 billion total transactions, and over $22 billion in total value locked (TVL), as reported on TRONSCAN. In addition, TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin across the globe, overtaking USDT on Ethereum since April 2021. The TRON network completed full decentralization in December 2021 and is now a community-governed DAO. Most recently in October 2022, TRON was designated as the national blockchain for the Commonwealth of Dominica, which marks the first time a major public blockchain partnered with a sovereign nation to develop its national blockchain infrastructure. On top of the government’s endorsement to issue Dominica Coin (“DMC”), a blockchain-based fan token to help promote Dominica’s global fanfare, seven existing TRON-based tokens - TRX, BTT, NFT, JST, USDD, USDT, TUSD, have been granted statutory status as authorized digital currency and medium of exchange in the country. TRONNetwork | TRONDAO | Twitter | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

August 30, 2024 11:57 AM Eastern Daylight Time

Image

Get Ready to Win Big—LHUNT Token Presale Now Live!

Spark Metro

The Crypto world never fails to amaze us in all new different ways. It has a new addition named LuckHunter with its ticker LHUNT. The presale of this LHUNT token is live, which is one of the game changing opportunities for the gamers and enthusiastic crypto investors. LuckHunter is an innovative online casino and gambling platform set to disrupt the online gambling industry. With a bag full of benefits, exclusively for the presale participants, don't wait and think much, grab the big opportunity now in this gaming industry. Exclusive Benefits for Early Adopters The LHUNT token is not just the regular crypto token, but it is a gateway to the world of rewards. The unique benefits it provides are as follows. 1. Up to 100% Worth of Presale Purchase Credits in Casino Imagine stepping into the world of Luckhunter.com with the presale purchase instantly transformed into casino credits. That’s right—participants in the LHUNT presale can receive up to 100% of their purchase value as casino credits, giving anyone a head start on the platform from day one. Whether being an experienced gambler or new to the scene, these credits allow gamblers to explore, play, and win big as soon as the platform goes live. 2. Huge Giveaways As a token of appreciation for your early support, presale.luckhunter.com is offering massive giveaways exclusively for presale participants. Expect a treasure trove of rewards, including crypto prizes, exclusive merchandise, and more. These giveaways aren’t just about luck—they’re designed to enhance user experience and keep the excitement going. 3. Staking Rewards The LHUNT presale isn’t just about buying tokens—it’s about investing in the future. Early participants will have access to enhanced staking rewards, allowing them to earn more LHUNT tokens simply by holding and staking their initial purchase. This is the only chance to maximize the investment while enjoying the perks of being an early adopter. 4. VIP Access Presale participants will be among the first to experience new games and features on Luckhunter.com. With VIP access, the buyers will have the inside track on the latest innovations, ensuring that they're always at the forefront of the gaming experience. This exclusive access is reserved only for those who believe in the platform from the start. 5. Exclusive Community Membership Joining the LHUNT presale means more than just buying tokens—it’s about becoming part of a community. Presale participants will gain access to a private community group where buyers can connect with like-minded individuals, share strategies, and engage directly with the Luckhunter.com team. This membership comes with special offers, insider information, and the chance to shape the future of the platform. A New Era in Crypto Gaming The LHUNT token presale represents more than just an investment—it’s the ticket to the next level of online gaming. By participating in this presale, investors not only secure their future in the crypto world but also gain access to a groundbreaking platform designed to reward its most loyal supporters. presale.luckhunter.com is set to redefine the casino and gambling experience, merging cutting-edge blockchain technology with the excitement of online gaming. Don’t miss this chance to be part of this revolution. The LHUNT token presale is live now, but it won’t last forever. Act Now—Secure Your LHUNT Tokens Today! This is your moment to step into the future of gaming. The LHUNT token presale is the chance to secure a piece of the action, enjoy unmatched benefits, and position yourself for massive rewards. Don’t wait—join the presale today and get ready to hunt for luck like never before. For more information and to participate in the LHUNT token presale, visit presale.luckhunter.com Or contact Telegram - https://t.me/LuckHunterCasino Twitter - https://x.com/LuckhuntrCasino Youtube - https://www.youtube.com/@LuckHunterCasino Email - team@luckhunter.com Contact Details Alex +1 302-497-6769 Apexreviews56@gmail.com

August 30, 2024 11:05 AM Eastern Daylight Time

Image

Bing Ventures to Present THE CRYPTO BASH at TOKEN2049 Singapore

Bing Ventures Limited

The one-of-a-kind event is scheduled for September 17, 2024, at Sinapore’s iconic rooftop bar CÉ LA VI. Speaker highlights include J17 Capital Partner Sky Lai, CoinFund Venture Investor Rishin Sharma, Protocol VC Investor Lacey-Ann Wisdom, Ocean Protocol Founder Bruce Pon, STIX CEO Taran Sabharwal, and many more. Bing Ventures, a pioneering venture capital firm backing early-stage projects and outstanding fund managers in Web3 and crypto, is cohosting with TOKEN2049 title sponsor BingX and AI-driven media platform Followin, THE CRYPTO BASH: Connect, Collaborate, Celebrate, on the sidelines of TOKEN2049 Singapore, the world’s largest crypto event. Scheduled to take place at Singapore’s iconic rooftop bar CÉ LA VI on September 17th, 2024, from 2 pm to 7 pm, THE CRYPTO BASH promises to captivate and enlighten attendees with an unparalleled fusion of innovation, connection, celebration, and scenic beauty. The event will bring together industry leaders, trailblazing entrepreneurs, future-minded investors, and blockchain enthusiasts for a remarkable festive experience of insight-sharing and networking. Activities include speeches and panel discussions on some of the most trending topics in the blockchain and Web3 industry, including decentralized AI (DeAI) and the Bitcoin ecosystem. Some of the confirmed speakers include: Bruce Pon, Founder of Ocean Protocol Rishin Sharma, Venture Investor at CoinFund Lacey Wisdom, Partner at Protocol VC Sky Lai, Partner at J17 Capital Carl Hua, Managing General Partner at Reforge Taran Sabharwal, CEO of STIX Rock Zhang, Founder of Network3 Luke Xie, Co-founder and CEO of SatLayer Markus Thielen, Founder of 10x Research Jason Gao, Investor Relations & Ecosystem at DFINITY Vivien Lin, Chief Product Officer at BingX & Head of BingX Labs Bruce Lan, General Partner at Bing Ventures Tracy Zhang, CMO at Followin This was the second year Bing Ventures hosted a premier side event during TOKEN2049 at CÉ LA VI. Last year’s edition saw over 1,000 registrants. This year’s event is set to be bigger and better than before, with the support of media partners including Cointelegraph, Beincrypto, Coingape, PANews, ChainCatcher, Foresight News, and Coinlive and participation organizations from the organizers' wide networks, including Bankless Ventures, Public Works, LookonChain, Blockless, MYX Finance, Aspecta, etc. Stay tuned for more details! Follow the organizers' social media channels and join the event group to stay updated with all the latest information about THE CRYPTO BASH before the event. Secure your spot at THE CRYPTO BASH by registering here (https://lu.ma/jt27o0wp) to RSVP. About Bing Ventures: Bing Ventures is a pioneering venture capital and research firm affiliated with crypto exchange BingX. Founded in 2021, it aims to support transformative blockchain and crypto ventures and outstanding fund managers driving the next wave of innovations. With a sector-agnostic, value-investing approach, it has a portfolio of more than 50 companies spanning infrastructure, DeFi, GameFi, Web3, and more, including, among others, Avail, Berachain, Manta Network, Pixelmon, Unisat, and Solv Protocol. Bing Ventures is also a Limited Partner (LP) of several leading crypto funds, including those managed by Hack VC, Bankless Ventures, Maven 11 Capital, IOSG Ventures, and Figment Capital. For more information, visit Bing Ventures' Official Website | LinkedIn | Twitter. Contact Details Jenny Liu +86 159 2140 1005 jenny@bing-ventures.com Company Website https://www.bing-ventures.com/

August 30, 2024 09:00 AM Eastern Daylight Time

Image

1 ... 70 71 72 73 74 ... 3772

Back